CASE REPORT

Crohn’s Disease Accompanied with Small Intestinal Extramedullary Plasmacytoma

Yoshinori Hanawa, Masaaki Higashiyama, Kazuki Horiuchi, Kana Ayaki, Suguru Ito, Akinori Mizoguchi, Shin Nishii, Akimori Wada, Kenichi Inaba, Nao Sugihara, Masaki Higashiyama, Kazuki Horiuchi, Kana Ayaki, Suguru Ito, Akinori Mizoguchi, Shin Nishii, Akimori Wada, Kenichi Inaba, Nao Sugihara

Abstract:
We herein present the case of an immunocompetent 63-year-old man who had previously undergone resection of Crohn’s disease (CD)-related small intestinal obstruction more than 30 years ago. He had not been receiving any medication for many years, but had recently started to suffer from ileus. A stenosed site of ileo-cecal anastomosis was identified and therefore was surgically resected, which was diagnosed as CD with small intestinal extramedullary plasmacytoma (EMP). The subsequent progression of CD was successfully controlled by anti-TNFα agents without any recurrence of EMP for over 3 years, implying the clinical benefit and safety of the biological therapy. This was the first known case of a patient who received anti-TNFα agents after a resection of small intestinal EMP accompanied with CD.

Key words: extramedullary plasmacytoma (EMP), plasmablastic neoplasm, plasmablastic lymphoma (PBL), Crohn’s disease (CD), anti-TNFα agents

(Intern Med Advance Publication) (DOI: 10.2169/internalmedicine.1687-18)

Introduction

There are two types of plasmacytoma pathologically: namely, solitary plasmacytoma of bone and extragosseous (extramedullary) plasmacytoma (EMP). Solitary plasmacytomas are single localized tumors consisting of monoclonal plasma cells with no physical or radiographical evidence of additional plasma cell tumors and no clinical features of plasma cell myeloma (PCM), including M protein, anemia, hypercalcemia, or renal failure (1). Histologically, EMP is composed of monomorphic, well-differentiated plasma cells, or atypical neoplastic plasma cells that are indistinguishable from plasmablastic lymphoma (PBL) (2). Among EMP, the most commonly encountered site is the upper airway, while the gastrointestinal (GI) tract is only rarely involved (3). In the GI tract, the stomach, liver and colon are the most frequent sites of EMP, whereas the small intestine (duodenum, jejunum and ileum) is a rare location (4).

Over the past few decades, there has been dramatic progress in the treatment of inflammatory bowel disease (IBD), including Crohn’s disease (CD). Now we can effectively use various immunosuppressive agents such as azathiopurine (AZA) and anti-TNFα agents worldwide. But some clinical problems remain regarding what medical therapy for IBD should be administered for patients with a past history of neoplastic disease. Actually, the ECCO guideline shows in the paragraph of management of IBD patients with past history of malignancy that “Physicians must be aware of the potential impact of immunosuppressants on cancers and on the risk of developing a second malignancy in cancer survivors” (5).
We herein present a rare case of CD accompanied with small intestinal EMP, who received anti-TNFα agents to control the progression of CD after a resection of EMP and thereafter remained recurrence free of EMP for more than 3 years after the surgery.

Case Report

A 63-year-old Japanese man re-visited our hospital in March 2015 suffering from a sense of abdominal distention and weight loss. He had a past history of undergoing two surgical operations in our hospital almost 30 years ago due to intestinal stenosis and a diagnosis of CD had been made histologically. He had been taking salazosulfapyridine for several years with no immunosuppressive agents, but he stopped visiting us after self-interruption of medication 7 years prior to this presentation and had taken no medication recently.

X-ray examinations and magnetic resonance enterocolonography (MREC) revealed an obstruction at the site of ileo-cecal anastomosis (Fig. 1A and B), which was thought to have been caused by CD. Colonoscopic findings also showed stenosis in the ileo-cecal anastomosis with ulcer formation (Fig. 1C and D). A stenotic lesion of small intestine had been removed surgically in April 2015. The macroscopic findings of the removed ileo-cecal anastomosis showed a stenosed lumen and longitudinal ulcers surrounded by white arrow heads (max 65 mm). Yellow bars indicate the histological accumulation of atypical lymphocytes observed in the area of longitudinal ulcers.

Figure 1. Image and macroscopic views of stenotic ileo-cecal anastomosis. (A and B) Magnetic resonance enterocolonography revealed ileo-cecal anastomatic obstruction. (C and D) Colonoscopic findings also showed the stenosis of ileo-cecal anastomosis with ulcer formation. (E) The macroscopic findings of the removed ileo-cecal anastomosis showed a stenosed lumen and longitudinal ulcers surrounded by white arrow heads (max 65 mm). Yellow bars indicate the histological accumulation of atypical lymphocytes observed in the area of longitudinal ulcers.
symptoms gradually worsened. A second FDG-PET / CT scan (September 2015) showed an uptake around the ileo-cecal anastomosis again. In order to distinguish between the local recurrence of EMP and a progression of CD, we performed step biopsies of the total small intestine by balloon-assisted enteroscopy examinations inserted both from the mouth and anus, which could not pass through the ileo-cecal anastomosis (January 2016). Since the pathological findings showed no specific finding without any evidence of recurrence, the narrowing lumen was thus considered to be due to a progression of CD. Thereafter, hypoalbuminemia improved and prednisolone was administered around June 2016.

Although there was a transient decrease in the elevated CRP, inflammation again worsened along with intermittent abdominal pain and distention. The ECCO guideline showed the risk of immunosuppressants on the recurrence of malignancy (5), but it also showed no obvious excessive risk of developing new or recurrent cancer while being treated with anti-TNFα therapy although this was only based on preliminary data (5). In addition, since thiopurines were supposed to increase the risk of lymphoma (5), we preferred not to use thiopurines to control CD. Therefore, after carefully explaining to the patient and his family about the estimated risks of recurrence and other side effects, we decided to start administering one of anti-TNFα agents adalimumab (ADA) without any combination of thiopurines (October 2016), because ADA was supposed to cause secondary failure less frequently due to less immunogenicity even without combination of thiopurine than infliximab (IFX) (8). But just after two injection of ADA, he suffered from bacterial pneumonia and entered the hospital again. ADA was suspended for a while and it seemed to become less effective after re-administration. We switched ADA to IFX without any combination of thiopurine (February 2017), and his abdominal symptom thereafter improved with a gradual amelioration of hypoalbuminemia. Since a third FDG-PET / CT scan in December 2017 showed a slight uptake around the anastomosis.

**Figure 2.** A histological examination of the resected stenotic ileo-cecal anastomosis. (A and B) The histological examination revealed that there was a dense accumulation of plasmablastoid cells with central oval nuclei with prominent nucleoli around the surface of the ulcer. (C to E) These atypical lymphocytes were immunohistologically positive for CD138 and MUM1, and negative for CD20. (F) Ki-67 scoring was about 60%. Each magnification: ×40 in A, ×400 in B to F.
of the small intestine, we performed anally inserted enteroscopy in January 2018 and were able to pass through the ileo-cecal anastomosis which could not be passed through 2 years previously, thus implying that the CD had been well controlled. Step biopsies simultaneously taken from the intestine showed no recurrence of the neoplasm, suggesting that the uptake around anastomosis observed in third FDG-PET / CT scan indicated inflammatory findings caused by CD. He has been doing well for over 3 years after the surgery with maintenance therapies of 5-ASA, ED, and IFX (May 2018).

**Discussion**

We herein describe a rare case of CD accompanied with small intestinal EMP, which is the first report including the clinical course of the treatments with anti-TNFα agents after the resection of the EMP.

In some cases of anaplastic plasmacytoma like ours, a definite distinction from PBL cannot be easily made (2), and a descriptive diagnosis, such as 'plasmablastic neoplasm, consistent with PBL or anaplastic plasmacytoma', may be acceptable according to the recently revised WHO classification in 2017 (1). But it is clinically important to distinguish anaplastic EMP and PBL because the optimal therapies and clinical courses are very different. Local radiotherapy is the preferred therapeutic modality for primary EMP owing to its radio-sensitivity (9). A surgical resection of the mass is also another good option. A retrospective study showed that there was no statistical difference in the overall survival between radiotherapy alone, radiotherapy plus surgery or surgery alone (10). EMP has a generally favorable prognosis with a 78% survival rate for 15 years and dissemination of EMP occurred in 15%, especially in the first three years (11). On the contrary, PBL has a poor prognosis with most patients dying within 2 years from initial presentation, and there are very few long-term survivors (12). PBL has been found in the oral cavity and other sites such as the GI tract, lymph nodes, and skin (13). The PBL is a high-grade malignant mature B-cell neoplasm characterized by a strong association with HIV and EBV infection (14, 15), and iatrogenic immunosuppression (16). The integration of EBV RNA into tumor cells is observed in about 60% of all PBL cases (7), but EMP is rarely associated with EBV and it also has a favorable prognosis (2, 11). A standard therapy has not yet been established for PBL and chemotherapies including R-CHOP are possible options (6). In our case, negativity for HIV and EBER, and non-compromised host with no usage of immunosuppressive agents before the surgery and subsequent good clinical course over 3 years even after the administration of immunosuppressive anti-TNFα agents for controlling CD suggested that the diagnosis of EMP in our case seemed to be clinically valid.

In recent clinical situations, the immunosuppressive agents are widely used and careful attention should be paid to what effects these agents have on the progression or recurrence of malignancy. The ECCO guideline showed the potential impact of immunosuppressants on cancers and on the risk of developing a second malignancy in cancer survivors with IBD (5). But preliminary data demonstrate no obvious excessive risk of developing new or recurrent cancer while being treated with anti-TNFα therapy. In addition, thiopurines, calcineurin inhibitors, and anti-TNFα agents should be stopped at least until cancer therapy is completed. Therefore, we used anti-TNFα agents to control CD after confirming that the neoplasm had been successfully removed by surgery with no residual lesion in image examinations and explaining him the risk of recurrence. There has been no case report using anti-TNFα agents to control CD after the treatment of EMP or PBL except for ours. Since plasmablastic neoplasm cases will possibly increase in the future along with the current wide-spread use of immunosuppressive agents, we hope that our case may therefore be informative for physicians who need to treat immune disease accompanied with EMP, and appropriate examinations to distinguish the criteria between PBL and anaplastic EMP should therefore be developed in the future.

EMP is a rare type of neoplasm that accounts for only 3-5% of all plasma cell tumors (17). The diagnosis of EMP requires the exclusion of associated PCM as shown by a negative finding of Bence-Jones protein in urine, normal serum electrophoresis and normal bone marrow biopsy (18, 19), and our present case met all the above criteria. Most EMP are found in the nasopharynx or upper respiratory tract (82.2%) and only 7.2% of cases involve the GI tracts (10). Among all segments of the GI tract, only 61 cases with EMP of the small intestine have so far been reported, which were reviewed by Rodrigo in 2012 (4). Among them, there was one case of EMP in the small intestine accompanied with an active lesion of CD in 1980’s (20). There was also another EMP case involving the colon accompanied with an active lesion of CD in 1990’s (21). Those two cases did not previously receive any immunosuppressive therapies. On the contrary, 4 cases among 5 CD cases with PBL received preceding immunosuppressive therapies (22-26), implying that PBL is strongly related with immunosuppressive therapies as already shown before (16). The causal relationship between CD and EMP seems to be very weak, but the co-localization of EMP with active CD lesions in 3 cases including ours suggests that the pathophysiology of CD might be related with the incidence of EMP (20, 21). As far as we could investigate, there have so far been no reports showing the relationship between intestinal surgery and the subsequent occurrence of EMP.

**Conclusion**

This is an informative case report on the indications of immunosuppressive agents to treat those with a past history of EMP to control the activity of immune diseases such as CD.

The authors state that they have no Conflict of Interest (COI).
References

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon, 2017.

2. Yau J, Wang J, Zhang W, Chen M, Chen J, Liu W. Solitary plasmacytoma associated with Epstein-Barr virus: a clinicopathologic, cytogenetic study and literature review. Ann Diagn Pathol 27: 1-6, 2017.

3. Thumallapally N, Moshref A, Mousa M, Terjanian T. Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA. BMC Cancer 17: 13, 2017.

4. Lopes da Silva R. Extramedullary plasmacytoma of the small intestine: clinical features, diagnosis and treatment. J Dig Dis 13: 10-18, 2012.

5. Annese V, Beaugerie L, Egan L, et al. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies. J Crohns Colitis 9: 945-965, 2015.

6. Castillo JJ, Winer ES, Stachurski D, et al. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma. Oncologist 15: 293-299, 2010.

7. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 89: 1413-1420, 1997.

8. Vermeire S, Gils A, Accossato P, Lula S, Marren A. Immunogenicity of biologics in inflammatory bowel disease. Therap Adv Gastroenterol 11: 1756283X17750355, 2018.

9. Chao MW, Gibbs P, Wirth A, Quong G, Guiney MJ, Liew KH. Radiotherapy in the management of solitary extramedullary plasmacytoma. Internal medicine journal 35: 211-215, 2005.

10. Alexiou C, Kau RJ, Dietzfelbinger H, et al. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer 85: 2305-2314, 1999.

11. Galieni P, Cavo M, Pulsoni A, et al. Clinical outcome of extramedullary plasmacytoma. Haematologica 85: 47-51, 2000.

12. Elyamany G, Al Mussaed E, Alzahrani AM. Plasmablastic Lymphoma: A Review of Current Knowledge and Future Directions. Adv Hematol 2015: 315289, 2015.

13. Castillo JJ, Reagan JL. Plasmablastic lymphoma: a systematic review. The Scientific World Journal 11: 687-696, 2011.

14. Castillo J, Pantanowitz L, Deuze BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol 83: 804-809, 2008.

15. Castillo JJ, Farman M, Beltran BE, et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer 118: 5270-5277, 2012.

16. Liu JJ, Zhang L, Ayala E, et al. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res 35: 1571-1577, 2011.

17. Doki T, Takeuchi O, Kaiho T, Tsuttiya S, Matsuzaki O, Miyazaki M. Primary isolated extramedullary plasmacytoma of the colon. Int J Colorectal Dis 23: 719-720, 2008.

18. Lee SH, Ahn BK, Baek SU, Chang HK. Primary Isolated Extramedullary Plasmacytoma in the Colon. Gastroenterology Res 6: 152-155, 2013.

19. Merritt JW Jr. Plasmacytoma of the gastro-intestinal tract. Annals of surgery 142: 881-888, 1955.

20. Robertson EJ, Al-Kaisi NK, Vareska GJ, Ponsky JL. Plasmacytoma of the ileum complicating Crohn’s disease: report of a case and review of the literature. Surgery 100: 916-923, 1986.

21. Ligato S, El-Naggar A, Cleary KR, Manning J. Extramedullary plasmacytoma mimicking primary colon carcinoma in a patient with Crohn’s disease. Case report and literature review. Archives of pathology & laboratory medicine 120: 279-282, 1996.

22. Maung SW, Desmond R, McHugh J, et al. A coincidence or a rare occurrence? A case of plasmablastic lymphoma of the small intestines following infliximab treatment for Crohn’s disease. Ann Hematol 95: 149-150, 2016.

23. Liu C, Varikatt W, P’Ng C H. Plasmablastic lymphoma presenting as a colonic stricture in Crohn’s disease. Pathology 46: 77-79, 2014.

24. Liu L, Charabaty A, Ozdemirli M. EBV-associated plasmablastic lymphoma in a patient with Crohn’s disease after adalimumab treatment. J Crohns Colitis 7: e118-e119, 2013.

25. Plaza R, Ponferrada A, Benito DM, et al. Plasmablastic lymphoma associated to Crohn’s disease and hepatitis C virus chronic infection. J Crohns Colitis 5: 628-632, 2011.

26. Redmond M, Quinn J, Murphy P, Patchett S, Leader M. Plasmablastic lymphoma presenting as a paravertebral mass in a patient with Crohn’s disease after immunosuppressive therapy. J Clin Pathol 60: 80-81, 2007.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).